LigaChem Biosciences Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 141080.KQ | BIOCON.NS | 0MGB.IL | 196170.KQ | 207940.KS | 166480.KQ | |
|---|---|---|---|---|---|---|
| Market cap | 2.35T | 592.87B | 296.78B | 14.70T | 70.76T | 77.00B |
| P/E (TTM) | — | 121.5 | 52.4 | — | — | — |
| Forward P/E | — | 33.3 | — | — | — | — |
| Price/book | — | 1.7 | 8.4 | — | — | — |
| Dividend yield | — | 0.15% | — | 0.14% | — | — |
| 1-year change | −60.92% | −10.58% | +93.74% | −49.87% | −20.37% | +12.78% |
| Today | +7.41% | +5.10% | +2.31% | +3.68% | +1.67% | −1.42% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All 141080.KQ news ›Ligachem Biosciences ADC Shows 50% Response Rate After Enhertu
Five of 10 Patients Previously Treated With Enhertu Saw Tumors Shrink Grade 3 Treatment-Related Adverse Events in 15.2% of 105 Patients Additional Trial Data to Be Presented at SABCS in December A drug candidate built on antibody-drug…
LigaChem Biosciences Doses First Patient in Trial of ADC "LCB02A" Targeting Gastric, Pancreatic Cancers
Published 16 Oct.2026 08:40(KST) LigaChem Biosciences has begun global clinical trials of LCB02A, a candidate antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2) that it developed in-h
Pharma and Biotech Stocks Surge in Tandem... Celltrion Up 6%, LigaChem Biosciences Up 8%
South Korean pharmaceutical and biotech stocks surged across the board in domestic trading. The rally was driven by concentrated buying as the healthcare sector led gains on Wall Street overnight, compounded by positive clinical results…
From the 4Search news index, newest first.
In the news
Mentioned with
Most coverage from
- finance.biggo.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.